Ono Pharmaceutical Co., Ltd.
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 11 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
5.7M | +0.04% | |
|
SCHWAB STRATEGIC TRUST-Schwab International Dividend Equity ETF
|
5.0M | +7.96% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
3.6M | +2.38% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
2.6M | 0.00% | |
|
Dimensional ETF Trust-Dimensional International Value ETF
|
1.4M | +9.74% | |
|
iShares Trust-iShares MSCI EAFE Small-Cap ETF
|
1.4M | +0.51% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
215.6K | +4.09% |
Dividend History
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥80 | 0.0% |
| 2024 | ¥80 | +3.9% |
| 2023 | ¥77 | +26.2% |
| 2022 | ¥61 | +20.8% |
| 2021 | ¥51 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥361,361M | ¥447,187M | ¥502,672M | ¥486,871M |
| Gross Profit | ¥267,850M | ¥337,124M | ¥375,547M | ¥338,921M |
| Operating Income | ¥103,196M | ¥141,963M | ¥159,936M | ¥59,748M |
| Pretax Income | ¥105,899M | ¥144,445M | ¥163,963M | ¥64,646M |
| Net Income | ¥80,519M | ¥112,723M | ¥127,977M | ¥50,047M |
| EPS | ¥162.16 | ¥230.79 | ¥266.57 | ¥106.41 |
| Operating Margin | 28.56% | 31.75% | 31.82% | 12.27% |
| Balance Sheet | ||||
| Total Assets | ¥739,203M | ¥882,437M | ¥913,668M | ¥1,064,046M |
| Total Equity | ¥655,906M | ¥741,869M | ¥792,961M | ¥782,451M |
| Total Liabilities | ¥83,297M | ¥140,568M | ¥120,707M | ¥281,595M |
| Cash | ¥69,112M | ¥96,135M | ¥166,141M | ¥204,567M |
| Interest-bearing Debt | ¥8,802M | ¥9,168M | ¥8,862M | ¥146,678M |
| Equity Ratio | 88.73% | 84.07% | 86.79% | 73.54% |
| D/E Ratio | 0.01 | 0.01 | 0.01 | 0.19 |
| Cash Flow | ||||
| Operating CF | ¥61,829M | ¥159,610M | ¥110,660M | ¥82,459M |
| Investing CF | ¥6,038M | -¥100,259M | ¥48,077M | -¥136,785M |
| Financing CF | -¥60,237M | -¥32,484M | -¥89,848M | ¥94,299M |
| Free CF | ¥49,552M | ¥145,113M | ¥89,831M | ¥74,469M |
| Efficiency | ||||
| ROE | 12.28% | 15.19% | 16.14% | 6.40% |
| ROA | 10.89% | 12.77% | 14.01% | 4.70% |
Latest IR Information
-
Notice Regarding Changes in Directors and Executive Officers
Announcement of scheduled reappointment of all six directors as of April 1, 2026, and at the shareholders meeting planned for June 2026, along with changes in executive officers.
Read more -
Notice Regarding Transfer of Distribution and Sales in Japan and Termination of Joint Promotion of SGLT2 Inhibitor "Forxiga® Tablets 5mg, 10mg"
As of March 31, 2026, the distribution and sales of Forxiga® Tablets in Japan will be transferred from Ono Pharmaceutical Co., Ltd. to AstraZeneca, and joint promotion will end. The sales forecast for fiscal 2026 is 80 billion yen.
Read more -
FY2026 Q3 Financial Summary [IFRS] (Consolidated)
For FY2026 Q3, revenue was 397.0 billion yen (6.0% YoY increase), operating income was 88.2 billion yen (24.8% YoY increase), and quarterly profit was 68.9 billion yen (21.8% YoY increase).
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥2,046
Rating Score: 3.25 (Based on 11 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has collaborations with Adimab LLC to discover novel antibody drugs; Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and Sibylla Biotech for central nervous system disorders. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
